Instructions for Authors 2021

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

AR provides for the prompt print and online publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work (without supplementary data), and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work or before the Acknowledgements); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures (graphs and photographs).** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Figures should be prepared at a width of 8 or 17cm with eligible symbols, lettering and numbers. The number of each figure must be indicated. Pages that include color figures should be subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Each table may have 2-10 vertical columns. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalgleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Res 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticanres.12924. (PMIDs and DOIs only if

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

**Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfills the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 5 days from submission, the author should contact the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for peer-review (single-blind) in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and Discussion should not be combined into one section.
   • Results given in figures should not be repeated in tables.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   • References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably in red. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. All Authors will be asked to supply author contribution and conflict of interest forms.

10. Articles submitted to AR may be rejected without review if:
    • they do not fall within the journal's policy.
    • they do not follow the instructions for authors.
    • language is unclear.
    • results are not sufficient to support a final conclusion.
    • results are not objectively based on valid experiments.
    • they repeat results already published by the same or other authors before the submission to AR.
    • plagiarism is detected by plagiarism screening services.

11. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

12. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

13. Authors who wish to organize and edit a special issue on a particular topic should contact the Managing Editor.

14. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2021 – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

- CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.

- CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online only and open access with Stanford University HighWire Press. For more information please visit our website www.cgp.iiarjournals.org.

- Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

- U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

- E-mail: journals@iiar-anticancer.org; IIAR WEBSITES: www.cgp.iiarjournals.org and www.iiarjournals.org

Selection of Recent Articles

Micro RNAs Promoting Growth and Metastasis in Preclinical In Vivo Models of Subcutaneous Melanoma. U.H. WEIDLE, S. AUSLÄNDER, U. BRINKMANN (Penzberg, Germany)


Stem-like Cells from Invasive Breast Carcinoma Cell Line MDA-MB-231 Express a Distinct Set of Eph Receptors and Ephrin Ligands. M. LUCERO, R. BADISA, N. MACK, S. CASSIM, M. ZDRALEVIC, J. POUYSSEGUR, K.F.A. SOLIMAN (Tallahassee, FL, USA; Monaco, Monaco; Nice, France)

Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. A. RIZZO, A.D. RICCI, S. TAVOLARI, G. BRANDI (Bologna, Italy)


Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV+ and HPV− Squamous Cell Carcinoma. B. KANSY, C. ADERHOLD, L. HUBER, S. LUDWIG, R. BIRK, A. LAMMERT, S. LANG, N. ROTTER, B. KRAMER (Essen; Mannheim; Marburg, Germany)

Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oosphageal Squamous Cell Carcinoma. S. UEDA, M. KANDA, Y. SATO, H. BABA, S. NAKAMURA, K. KANDA, D. SHIMIZU, K. SAWAKI, T. FUJII, Y. KODERA, S. NOMOTO (Nagoya; Akita; Toyama, Japan)

Fusion of the Lumican (LU M) Gene With the Ubiquitin Specific Peptidase 6 (USP6) Gene in an Aneurysmal Bone Cyst Carrying a t(12;17)(q21;p13) Chromosome Translocation. I. PANAGOPOULOS, L. ORUPOVA, K. ANDERSEN, I. LOBMAIER, M. LUND-IVERSEN, F. MICCI, S. HEIM (Oslo, Norway)

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer. M. CHEVALLIER, P. TSANTOULIS, A. ADDEO, A. FRIELAENDER (Geneva, Switzerland)

Long Noncoding RNA ANROC on the INK4 Locus Functions to Suppress Cell Proliferation. Y. KOTAKE, T. TSURUDA (Fukuoka, Japan)


General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance (3 months from submission).

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR WEBITES: www.iiar-anticancer.org and www.iiarjournals.org

International Journal of Experimental and Clinical Pathophysiology and Drug Research
Published bimonthly by the International Institute of Anticancer Research
Available online only and open access with Stanford University HighWire Press

Selection of Recent Articles
Sutereless Surgical Orthotopic Implantation Technique of Primary and Metastatic Cancer in the Liver of Mouse Models. H. NISHINO, H.M. HOLLANDSWORTH, N. SUGISAWA, J. YAMAMOTO, Y. TASHIRO, S. INUBUSHI, K. HAMADA, Y. SUN, H. LIM, S. AMIRFAKHIRI, F. FILEMONI, R.M. HOFFMAN, M. BOUVET (San Diego, CA, USA; Kyoto, Japan)


SMN Protein Contributes to Skeletal Muscle Cell Maturation Via Caspase-3 and Akt Activation. S. ANDO, M. TANAKA, N. CHINE, S. NAKAMURA, M. SHIMA ZAWA, H. HARA (Gifu, Japan)

Comparison of TMA Technique and Routine Whole Slide Analysis in Evaluation of Proliferative Markers Expression in Laryngeal Squamous Cell Cancer. U. CIESIELSKA, A. PIOTROWSKA, C. KOBIERZYCKI, W. PASTUSZEWSKI, M. PODHORSKA-OKOLOW, P. DZIEGIEL, K. NOWINSKA (Wrocław, Poland; Namsos, Norway)

Leucocyte Count Does Not Improve the Diagnostic Performance of a Diagnostic Score (DS) in Distinguishing Acute Appendicitis (AA) from Nonspecific Abdominal Pain (NSAP). J. MEK LIN, M. ES KELINEN, K. SYRJANEN, M. ES KELINEN ( Kuopio; Kaarina, Finland; Barretos, Brazil)


Cutaneous Stomal Recurrence of Colorectal Cancer After Curative Rectal Cancer Surgery – A Case Report and Systematic Review. S. DAVEY, K. McCARTHY (Bristol, UK)

Knockout of TRPV1 Exacerbates Ischemia-reperfusion-induced Renal Inflammation and Injury in Obese Mice. B. ZHONG, S. MA, D.H. WANG (East Lansing, MI, USA)

In Vitro and In Vivo Biocompatibility Analysis of a New Transparent Collagen-based Wound Membrane for Tissue Regeneration in Different Clinical Indications. O. JUNG, M. RADER KOVIC, S. STOJANOVIĆ, C. LINDNER, M. BATIC N, O. GÖRKE, J. PISSAREK, A. PRÖHL, S. NAJMAN, M. BARBECK (Rostock; Berlin, Germany; Niš, Serbia)

Hepatocellular Carcinoma-associated microRNAs Induced by Hepatoma-derived Growth Factor Stimulation. H. ENOMOTO, H. NAKAMURA, H. NISHIKAWA, T. NISHIMURA, Y. IWATA, S. NISHIGUCHI, H. IJI MA (Hyogo; Osaka, Japan)

An Improved Encapsulation Method for Cryopreserving Hepatocytes for Functional Transplantation Using a Thermo-reversible Gelation Polymer. K. YAMADA, T. AOKI, Y. ENAMI, Y. TASHIRO, Z. ZEHAO U, T. KOIZUMI, T. KUSANO, K. MATSUDA, Y. WADA, H. SHIBATA, K. TOMICHA, K. SIRIRAT WAO WONG, R.M. HOFFMAN, M. MURAKAMI (Tokyo, Japan; San Diego, CA, USA)
Preoperative Pre-albumin Concentration as a Predictor of Short-term Outcomes in Elderly Patients With Colorectal Cancer. S. SATO, M. SHIOZAWA, S. NUKADA, K. IGUCHI, K. KAZAMA, Y. ATSUMI, M. NUMATA, H. TAMAGAWA, K. TANAKA, T. OSHIMA, Y. RINO (Yokohama, Japan) ..................................


Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy. Y.-H. HUANG, Y.-S. HUNG, C.-C. LAI, M.-M. HO, K.-Y. YEH, C. YANG, C.-H. LU, C.-K. TSENG, N.-M. TSANG, C.-Y. HUNG, S.-W. HSUEH, P.-H. CHANG, Y.-W. HO, Y.-C. LIN, W.-C. CHOU (Taoyuan; Keelung; New Taipei City; Chiayi; Taipei, Taiwan, ROC) ..........................................

Pancreaticoduodenectomy at a Non-high-volume Center and Efforts to Perform Safe Surgery. T. YAMANE, D. IZUMI, S. KINOSHITA, C. SHIRAKAMI, K. MORITA, S. IKESHIMA, K. HORINO, S. SHIMADA, H. BABA (Yatsusiro; Kumamoto, Japan) ..............................................................................................................


Chemoembolization for Hepatocellular Carcinoma in Patients With Inferior Vena Caval/Right Atrial Tumor Thrombi Without Hepatic Vein Invasion. M. KIM, H.-C. KIM, J.W. CHUNG (Seoul, Republic of Korea) ...........

Intrahepatic Cholangiocarcinoma Coexisting With Multiple Bile Duct Adenoma Treated as Liver Metastasis from a Pancreatic Neuroendocrine Tumor. E. ODA, K. YAMAMURA, Y. HARA, K. MATSUMURA, S. AKAHOSHI, H. YUKI, T. MOTOHARA, H. MIYAMOTO, K. KINOSHITA, F. MATSUMURA, K. OHNISHI, Y. KOMOHARA, T. BEPPU (Kumamoto; Fukuoka, Japan) ............................................................... 5249

ABSTRACTS OF THE 31st ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO). 30 September - 2 October 2021 (Virtual Meeting) ............................................................................................................. 5255-5332
IGUCHI, S. SAWAZAKI, T. AYOYAMA, A. TAMAGAWA, S. SATO, A. HIGUCHI, N. SUGANO, T. GODAI, H. TAMAGAWA, H. SAEKI, T. OSHIMA, M. SHIOZAWA, N. YUKAWA, Y. RINO (Yokohama; Fujisawa, Japan) .......................................................... 5097

Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case Study. D. ANZELLINI, V. DE SANCTIS, M. VALERIANI, C. REVERBERI, L. MARINELLI, M. MASSARO, G. VULLO, G. FACONDO, R.C. SIGILLO, E. TOSI, M.F. OSTI (Rome, Italy) .................................................. 5107

The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors. J. VODICKA, M. SKALA, J. SEBEK, V. TRESKA, J. FICHTL, K. PROCHAZKOVA, B. VANKOVA, M. SVATON, O. TOPOLCAN, M. BLUDOVSKA, R. KUCERA (Pilsen, Czech Republic) ............ 5117


Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy. T. MATSUBARA, F. HIRAI, M. YAMAGUCHI, M. HAMATAKE (Fukuoka, Japan) ............... 5157

Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy. S. KOPELKE, T. BARTSCHT, S.E. SCHILD, S. TVILSTED, T.W. KAER, D. RADES (Lübeck, Germany; Scottsdale, AZ, USA; Konge; Roskilde, Denmark) ................................................................. 5165


Clinical Significance of 18F-fluorodeoxyglucose and Glucose Transporter 1 mRNA in Clear Cell Renal Cell Carcinoma. H. BETSU, S. SAKAMOTO, Y. KAJI, A. NUKUI, M. KOBAYASHI, M. YASHI, K. HAYASHI, N. ANZAI, T. KAMAI (Mibu; Akashi; Utsunomiya; Chiba, Japan) ........................................................................................................... 5179


Contents continued on the preceding page

Symptom Outcomes of Cancer Patients With Clival Metastases Treated With Radiotherapy: A Study of 44 Patients. R. STURGIS, A. MACK, S. KIM, J. MAIER, E.I. HEATH (Detroit, MI, USA) ................................................................. 5001


Vascularized Bone Graft Reconstruction Following Bone Tumor Resection at a Multidisciplinary Sarcoma Center: Outcome Analysis. S.M. GORSKI, C. DONG, A.H. KRIEG, M. HAUG (Basel, Switzerland) ....... 5015

Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer. V. LUENGAS-WUERZINGER, F. RAWERT, S. CLAßEN-VON SPEE, S. BARANSI, E. SCHULER, K. CARRIZO, P. MALLMANN, B. LAMPE (Düsseldorf; Cologne, Germany) ................................................. 5025

A Posterior-Anterior Cephalometric Study of Skull Symmetry in Patients With Neurofibromatosis Type 1. R.E. FRIEDRICH, G. CHRIST, H.T. SCHEUER, H.A. SCHEUER (Hamburg, Germany) ................................................. 5033

Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients. N. VÄHÄAHO, L. HAKAMIES-BLOMQVIST, C. BLOMQVIST, P-L. KELLOKUMPU-LEHTINEN, R. HUOVINEN, T. SAARTO, C. HAKULINEN (Helsinki; Tampere; Turku, Finland) ............................................................... 5045

Detectability of Lung Nodules in Ultra-low Dose CT. S. JANSSEN, D. OVERHOFF, M.F. FROELICH, S.O. SCHÖNENBERG, N. RATHMANN (Mannheim, Germany) ............................................................... 5053


Risk Factors for Sleep Disturbances in Patients Scheduled for Radiotherapy of Head-and-Neck Cancer. D. RADES, S. KOPELKE, T. SOROR, T. BARTSCHT, S. TVILSTED, T.W. KJAER, S.E. SCHILD (Lübeck, Germany; Koge; Roskilde, Denmark; Scottsdale, AZ, USA) ............................................................... 5065

The New Generation Immunochemical Test for Fecal Occult Blood (ColonView Quick Test) Shows a High Diagnostic Accuracy in Colorectal Cancer Detection. J. MEKLIN, M. ESKELINEN, D.P. GUIMARAES, T. SELANDER, J. INKINEN, T. TIUSANEN, K. SYRJÄNEN, M. ESKELINEN (Kuopio; Helsinki; Kaarina, Finland; Barretos, Brazil). ........................................................................................................... 5071

Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer. R.E. FRIEDRICH, E. MADANI (Hamburg, Germany) ........................................................................................................... 5081


Can D3 Lymph Node Dissection for Patients With Colon Cancer With a Poor C-Reactive Protein/Albumin Ratio Improve Survival Outcomes? Y. ATSUMI, M. NUMATA, K. KAZAMA, S. KAWAHARA, M. JU, K. 5097

Contents continued on the preceding page
Ponatinib Exerts an Inhibitory Effect on Collagen-induced Platelet Aggregation and Generation of Coated-Platelets. G. MEZEI, P. BATÁR, L. KOZMA, Á. ILLÉS, J. KAPPELMAYER, I.B. DEBRECENI (Debrecen, Hungary) ...... 4867


Rapalink-1 and Hydroxychloroquine Exhibit an Additive Effect in Undifferentiated Pleomorphic Sarcoma by Inducing Apoptosis. T. NEGAYAMA, Y. ISHIBASHI, O. NAKAMURA, Y. NOMURA, Y. KAJI, T. YAMAMOTO (Kagawa, Japan) .................. 4885


Antibody to Interleukin-6 Receptor Inhibits In Vivo Growth of Human Colorectal Carcinoma Cell Xenografts. Y.-C. CHUNG, Y.-L. KU, H.-C. CHIANG, W.-C. LIU, T.-Y. KAO, C.-H. YANG, C.-C. HUANG, C.-P. HSU (Taichung; Hsinchu, Taiwan, ROC) .................................................................................................................... 4907

Intracellular IL-33 Attenuates Extracellular IL-33-induced Cholangiocarcinoma Cell Proliferation and Invasion via NF-kB and GSK-3β Pathways. S. YANGNGAM, S. THONGCHOT, K. VAETEEWOOTTACHARN, P. THUWAJIT, M.A. HERMOSO, S. OKADA, C. THUWAJIT (Bangkok; Khon Kaen, Thailand; Santiago, Chile; Kumamoto, Japan) .......................................................................................... 4917


c-Myc-driven Hepatocarcinogenesis. H. MOON, H. PARK, S.W. RO (Gyeonggi-do, Republic of Korea) ...... 4937

The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression. H. KINOSHITA, O. SHIMOZATO, T. ISHII, H. KAMODA, Y. HAGIWARA, T. TSUKANISHI, S. OHTORI, T. YONEMOTO (Chiba, Japan) ........................................................................................................... 4947


Comparative Anticancer Activity and Molecular Docking of Different Isatin-Based Scaffolds. B.A. ESPINOSA-RODRIGUEZ, A.M. NIETO-MORENO, E.U. ARREDONDO-ESPINOZA, F.G. AVALOS-ALANIS, I. BALDERAS-RENTERIA (Nuevo Leon, Mexico) ...................................................................................................................... 4969

The Expression Levels of Vinculin in Pancreatic Cancer Tissues Significantly Correlates With Patient Survival. S. ISLAM, T. KITAGAWA, T. AZUMA, Y. KURAMITSU (Hokkaido; Tokyo, Japan) ................................................................. 4979

Clinical Studies


Contents continued on the preceding page
Ethylmalonic Encephalopathy 1 Protein Is Increased in Colorectal Adenocarcinoma. E. OZLUK, D. COPPOLA, I.Z. MOHAMMAD, T. ISLAM, G. GHALI, C.G. KEVIL, R.E. SHACKELFORD (Shreveport, LA; Tampa, FL, USA) .............................................................................................................................................. 4719

Plumbagin Induces Cytotoxicity via Loss of Mitochondrial Membrane Potential and Caspase Activation in Metastatic Retinoblastoma. R. GHARBARAN, C. SHI, O. ONWUMERE, S. REDENTI (New York, NY, USA) .............................................................................................................................................. 4725

Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells. S. KARLSSON, M.A. DIAZ CRUZ, M. FARESJÖ, A. PAPADOPOULOU KHAMOU, D. LARSSON (Jönköping; Gothenburg, Sweden) .............................................................................................................................................. 4733

Heat Shock Protein 105 as an Immunotherapeutic Target for Patients With Cervical Cancer. K. NOSAKA, S. SUZUKI, T. YOSHIKAWA, M. SHIMOMURA, K. KITAMI, K. YOSHIDA, M. YOSHIHARA, F. KIKKAWA, T. NAKATSURA, H. KAIJYAMA (Nagoya; Kashiwa, Japan) .............................................................................................................................................. 4741

Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization. M. TAKAI, K. KAWAKAMI, Y. FUJITA, T. KATO, D. KATO, K. IINUMA, T. KOIE, M. ITO, K. MIZUTANI (Gifu; Tokyo, Japan) .............................................................................................................................................. 4753

Anti-inflammatory and Anti-thrombotic Efficacy of Targeted Ultrasound Microbubbles on LPS-induced HUVEC Cells. J. SUN, S. PAN, H. YU, H. HU, Y. SUN, Z. YANG, R.M. HOFFMAN, H. YUAN (Hangzhou, PR China; San Diego, CA, USA) .............................................................................................................................................. 4761


Effects of Hypoxia on Proliferation and Apoptosis of Osteosarcoma Cells. S.-Y. YANG, E. GARCIA, W. XIA, A. WANG (Wichita, KS, USA; Zunyi, PR China) .............................................................................................................................................. 4781

Linker Threonine-phosphorylated Smad2/3 Is a Biomarker of Colorectal Neoplastic Stem-like Cells that Correlates With Carcinogenesis. S. MIYAMOTO, T. FUKUI, S. HORITANI, Y. TANIMURA, Y. MATSUMOTO, R. SUZUKI, Y. TAKAHASHI, M. KISHIMOTO, T. TOMIYAMA, A. NISHIO, K. OKAZAKI, M. NAGANUMA (Hirakata, Japan) .............................................................................................................................................. 4789

Significant Association of CCND1 Genotypes With Susceptibility to Childhood Acute Lymphoblastic Leukemia. P.-C. HSU, J.-S. PEI, C.-C. CHEN, W.-S. CHANG, Y.-T. CHIN, T.-L. HUANG, J.-S. YANG, Y.-C. WANG, J.-C. CHEN, Y.-N. HSU, C.-W. TSAI, D.-T. BAU (Taoyuan; Taichung; Changhua, Taiwan, ROC) .............................................................................................................................................. 4801


Impact of Oncogenic Targets Controlled by Tumor-Suppressive miR-30a-5p in Pancreatic Ductal Adenocarcinoma. P. NEPAL, Y. HOZAKA, T. TANAKA, M. WADA, S. ASAI, C. MINEMURA, T. IDICHI, T. ARIGAMI, H. KURAHARA, N. SEKI, T. OHTSUKA (Kagoshima; Chiba, Japan) .............................................................................................................................................. 4821

REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in A Mouse Model of Malignant Mesothelioma. K. ARAKI, N. YAMAMURO, N. TOMONOBU, H. KUMON (Okayama; Nogi-machi; Niimi, Japan) .............................................................................................................................................. 4837

Infiltration of CD204-overexpressing Macrophages Contributes to the Progression of Stage II and III Colorectal Cancer. Y. TADA, Y. MATSUMI, K. HARA, W. MIYAUCHI, K. SUGESAWA, C. UEJIMA, A. TANIO, K. KIHARA, M. YAMAMOTO, S. TAKANO, T. SAKAMOTO, Y. NAKAYAMA, T. HASEGAWA, Y. FUJIWARA (Yonago, Japan) .............................................................................................................................................. 4857

Contents continued on the preceding page